Alnylam Pharmaceuticals, Inc. ALNY
1 trading plan running, 11 Form 144 notices for $12.9M
10-Q, 10-K and Form 144What ALNY's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Sep 12, 2024 to Aug 6, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Tolga Tanguler Chief Commercialization Officer |
Adopted 10b5-1 plan | Aug 24, 2026 | 10-Q Oct 29, 2026 | ||
What the company wroteTolga Tanguler, Chief Commercialization Officer On August 24, 2026, Tolga Tanguler, our Chief Commercialization Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 22,438 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from November 23, 2026 to August 6, 2027. The plan is scheduled to terminate on August 6, 2027, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan. | |||||
| Pushkal Garg, M.D Chief Research and Development Officer |
Adopted 10b5-1 plan | Nov 20, 2025 | 10-K Feb 12, 2026 | ||
What the company wrotePushkal Garg, M.D., Chief Research and Development Officer On November 20, 2025, Pushkal Garg, M.D. our Chief Research and Development Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Garg, acting through a broker, may sell up to an aggregate of 25,418 shares of our common stock received upon the settlement of awards granted to Dr. Garg as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from February 27, 2026 to November 1, 2026. The plan is scheduled to terminate on November 1, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Garg or the broker, or as otherwise provided in the plan. | |||||
| Tolga Tanguler Chief Commercial Officer |
Adopted 10b5-1 plan | Nov 14, 2025 | 10-K Feb 12, 2026 | ||
What the company wroteTolga Tanguler, Chief Commercial Officer On November 14, 2025, Tolga Tanguler, our Chief Commercial Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 25,782 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from February 13, 2026 to November 15, 2026. The plan is scheduled to terminate on November 15, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan. | |||||
| Kevin J. Fitzgerald, Ph.D Chief Scientific Officer |
Adopted 10b5-1 plan | Aug 14, 2025 | 10-Q Oct 30, 2025 | ||
What the company wroteKevin J. Fitzgerald, Ph.D., Chief Scientific Officer On August 14, 2025, Kevin J. Fitzgerald, Ph.D., our Chief Scientific Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Fitzgerald, acting through a broker, may sell up to an aggregate of 30,013 shares of our common stock received upon the settlement of awards granted to Dr. Fitzgerald as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from November 12, 2025 to August 15, 2026. The plan is scheduled to terminate on August 15, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Fitzgerald or the broker, or as otherwise provided in the plan. | |||||
| Yvonne L. Greenstreet, M.D Chief Executive Officer and Director |
Adopted 10b5-1 plan | Aug 13, 2025 | 10-Q Oct 30, 2025 | ||
What the company wroteYvonne L. Greenstreet, M.D., Chief Executive Officer and Director On August 13, 2025, Yvonne L. Greenstreet, M.D., our Chief Executive Officer and a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Dr. Greenstreet, acting through a broker, may sell up to an aggregate of 25,650 shares of our common stock received upon the settlement of awards granted to Dr. Greenstreet as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from November 11, 2025 to May 14, 2026. The plan is scheduled to terminate on May 14, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Greenstreet or the broker, or as otherwise provided in the plan. | |||||
| Colleen F. Reitan Director |
Adopted 10b5-1 plan | Jun 10, 2025 | 10-Q Jul 31, 2025 | ||
What the company wroteColleen F. Reitan, Director On June 10, 2025, Colleen F. Reitan, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Ms. Reitan, acting through a broker, may sell up to an aggregate of 18,000 shares of our common stock received upon the exercise of options granted to Ms. Reitan as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from September 9, 2025 to May 15, 2026. The plan is scheduled to terminate on May 15, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Ms. Reitan or the broker, or as otherwise provided in the plan. | |||||
| Tolga Tanguler Chief Commercial Officer |
Adopted 10b5-1 plan | May 27, 2025 | 10-Q Jul 31, 2025 | ||
What the company wroteTolga Tanguler, Chief Commercial Officer On May 27, 2025, Tolga Tanguler, our Chief Commercial Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 3,474 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from August 29, 2025 to May 10, 2026. The plan is scheduled to terminate on May 10, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan. | |||||
| Dennis A. Ausiello, M.D. Director |
Adopted 10b5-1 plan | May 15, 2025 | 10-Q Jul 31, 2025 | ||
What the company wroteDennis A. Ausiello, M.D., Director On May 15, 2025, Dennis A. Ausiello, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Dr. Ausiello, acting through a broker, may sell up to an aggregate of 31,448 shares of our common stock received upon the exercise of options granted to Dr. Ausiello as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from August 13, 2025 to May 1, 2026. The plan is scheduled to terminate on May 1, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Ausiello or the broker, or as otherwise provided in the plan. | |||||
| Michael W. Bonney Director |
Adopted 10b5-1 plan | Nov 12, 2024 | 10-K Feb 13, 2025 | ||
What the company wroteMichael W. Bonney, Director On November 12, 2024, Michael W. Bonney, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Bonney, acting through a broker, may sell up to an aggregate of 22,500 shares of our common stock received upon the exercise of options granted to Mr. Bonney as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from February 12, 2025 to June 3, 2026. The plan is scheduled to terminate on June 3, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Bonney or the broker, or as otherwise provided in the plan | |||||
| Tolga Tanguler Chief Commercial Officer |
Adopted 10b5-1 plan | Sep 12, 2024 | 10-Q Oct 31, 2024 | ||
What the company wroteTolga Tanguler, Chief Commercial Officer On September 12, 2024, Tolga Tanguler, our Chief Commercial Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 4,070 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from December 13, 2024 to May 10, 2025. The plan is scheduled to terminate on May 10, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan. | |||||
| Yvonne L. Greenstreet Chief Executive Officer and Director |
Adopted 10b5-1 plan | Sep 12, 2024 | 10-Q Oct 31, 2024 | ||
What the company wroteYvonne L. Greenstreet, MBChB, MBA, Chief Executive Officer and Director On September 12, 2024, Yvonne L. Greenstreet, MBChB, MBA, our Chief Executive Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Greenstreet, acting through a broker, may sell up to an aggregate of 50,937 shares of our common stock received upon the settlement of awards granted to Dr. Greenstreet as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from December 16, 2024 to June 6, 2025. The plan is scheduled to terminate on June 6, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Greenstreet or the broker, or as otherwise provided in the plan. | |||||
| Pushkal P. Garg Chief Medical Officer |
Adopted 10b5-1 plan | Sep 11, 2024 | 10-Q Oct 31, 2024 | ||
What the company wrotePushkal P. Garg, Chief Medical Officer On September 11, 2024, Pushkal P. Garg, our Chief Medical Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Garg, acting through a broker, may sell up to an aggregate of 94,925 shares of our common stock received upon the settlement of awards granted to Dr. Garg as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from December 12, 2024 to December 18, 2025. The plan is scheduled to terminate on December 18, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Garg or the broker, or as otherwise provided in the plan. | |||||
| David E.I. Pyott Director |
Adopted 10b5-1 plan | Sep 5, 2024 | 10-Q Oct 31, 2024 | ||
What the company wroteDavid E.I. Pyott, Director On September 5, 2024, David E.I. Pyott, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Pyott, acting through a broker, may sell up to an aggregate of 7,440 shares of our common stock received upon the exercise of options granted to Mr. Pyott as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from January 1, 2025 to December 17, 2025. The plan is scheduled to terminate on December 17, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Pyott or the broker, or as otherwise provided in the plan. | |||||
| Kevin Fitzgerald Executive Vice President, Chief Scientific Officer |
Adopted 10b5-1 plan | May 10, 2024 | 10-Q Aug 1, 2024 | ||
What the company wroteKevin Fitzgerald, Ph.D., Executive Vice President, Chief Scientific Officer On May 10, 2024, Kevin Fitzgerald, Ph.D., our Executive Vice President, Chief Scientific Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Fitzgerald, acting through a broker, may sell up to an aggregate of 50,634 shares of our common stock received upon the settlement of awards granted to Dr. Fitzgerald as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from August 11, 2024 to May 10, 2025. The plan is scheduled to terminate on May 10, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Fitzgerald or the broker, or as otherwise provided in the plan. | |||||
| Dennis A. Ausiello Director |
Adopted 10b5-1 plan | May 3, 2024 | 10-Q Aug 1, 2024 | ||
What the company wroteDennis A. Ausiello, M.D., Director On May 3, 2024, Dennis A. Ausiello, M.D., a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Dr. Ausiello, acting through a broker, may sell up to an aggregate of 20,250 shares of our common stock received upon the exercise of options granted to Dr. Ausiello as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from August 5, 2024 to May 20, 2025. The plan is scheduled to terminate on May 20, 2025, subject to earlier termination upon the sale of all shares subject to the plan upon termination by Dr. Ausiello or the broker, or as otherwise provided in the plan. | |||||
| Yvonne L. Greenstreet Chief Executive Officer and Director |
Adopted 10b5-1 plan | Mar 12, 2024 | 10-Q May 2, 2024 | ||
What the company wroteYvonne L. Greenstreet, MBChB, MBA, Chief Executive Officer and Director On March 12, 2024, Yvonne L. Greenstreet, MBChB, MBA, our Chief Executive Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Greenstreet, acting through a broker, may sell up to an aggregate of 37,241 shares of our common stock received upon the settlement of awards granted to Dr. Greenstreet as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from June 19, 2024 to March 7, 2025. The plan is scheduled to terminate on March 7, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Greenstreet or the broker, or as otherwise provided in the plan. | |||||
| Amy W. Schulman Director |
Adopted 10b5-1 plan | Feb 28, 2024 | 10-Q May 2, 2024 | ||
What the company wroteAmy W. Schulman, Director On February 28, 2024, Amy W. Schulman, Chair of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Ms. Schulman, acting through a broker, may sell up to an aggregate of 30,200 shares of our common stock received upon the exercise of options granted to Ms. Schulman as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from May 29, 2024 to November 15, 2024. The plan is scheduled to terminate on November 15, 2024, subject to earlier termination upon the sale of all shares subject to the plan upon termination by Ms. Schulman or the broker, or as otherwise provided in the plan. | |||||
| David E.I. Pyott Director |
Adopted 10b5-1 plan | Aug 11, 2023 | 10-Q Nov 2, 2023 | ||
What the company wroteOn August 11, 2023, David E.I. Pyott, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Pyott, acting through a broker, may sell up to an aggregate of 32,450 shares of our common stock received upon the exercise of options granted to Mr. Pyott as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from November 16, 2023 to November 15, 2024. The plan is scheduled to terminate on November 15, 2024, subject to earlier termination upon the sale of all shares subject to the plan upon termination by Mr. Pyott or the broker, or as otherwise provided in the plan. | |||||
| Michael W. Bonney Director |
Adopted 10b5-1 plan | Aug 10, 2023 | 10-Q Nov 2, 2023 | ||
What the company wroteOn August 10, 2023, Michael W. Bonney, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Bonney, acting through a broker, may sell up to an aggregate of 30,000 shares of our common stock received upon the exercise of options granted to Mr. Bonney as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from November 13, 2023 to December 17, 2024. The plan is scheduled to terminate on December 17, 2024, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Bonney or the broker, or as otherwise provided in the plan. | |||||
| Tolga Tanguler Chief Commercial Officer |
Adopted 10b5-1 plan | May 18, 2023 | 10-Q Aug 3, 2023 | ||
What the company wroteOn May 18, 2023, Tolga Tanguler, our Chief Commercial Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 20,024 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from August 16, 2023 to May 10, 2024. The plan is scheduled to terminate on May 10, 2024, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan. | |||||
| Phillip A. Sharp member of our board of directors |
Adopted 10b5-1 plan | May 16, 2023 | 10-Q Aug 3, 2023 | ||
What the company wroteOn May 16, 2023, Phillip A. Sharp, Ph.D., a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Dr. Sharp, acting through a broker, may sell up to an aggregate of 63,750 shares of our common stock received upon the exercise of options granted to Dr. Sharp as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from September 1, 2023 to June 3, 2024. The plan is scheduled to terminate on June 3, 2024, subject to earlier termination upon the sale of all shares subject to the plan upon termination by Dr. Sharp or the broker, or as otherwise provided in the plan. | |||||
| David E.I. Pyott member of our board of directors |
Adopted 10b5-1 plan | – | 10-K Feb 12, 2026 | ||
What the company wroteDavid E.I. Pyott, Director On November 12, 2025, David E.I. Pyott, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Pyott, acting through a broker, may sell up to an aggregate of 7,610 shares of our common stock received upon the exercise of options granted to Mr. Pyott as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from February 11, 2026 to October 14, 2026. The plan is scheduled to terminate on October 14, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Pyott or the broker, or as otherwise provided in the plan | |||||
Show the other 14 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 4, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Oct 2, 2026 | SUPRAN BRYAN Officer |
1,758 | $399K |
| Jun 1, 2026 | PYOTT DAVID E I Director |
3,830 | $1.1M |
| Apr 6, 2026 | McLaughlin Melissa Officer |
2,286 | $732K |
| Mar 5, 2026 | Fitzgerald Kevin Joseph Officer |
658 | $213K |
| Mar 5, 2026 | Garg Pushkal Officer |
2,404 | $778K |
| Mar 3, 2026 | Fitzgerald Kevin Joseph Officer |
1,652 | $531K |
| Mar 3, 2026 | Garg Pushkal Officer |
1,775 | $570K |
| Feb 27, 2026 | Garg Pushkal Officer |
4,627 | $1.5M |
| Feb 17, 2026 | Fitzgerald Kevin Joseph Officer |
2,041 | $678K |
| Jan 13, 2026 | Fitzgerald Kevin Joseph Officer |
2,290 | $845K |
| Nov 17, 2025 | Fitzgerald Kevin Joseph Officer |
12,128 | $5.4M |
Show the other 3 notices
From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALNY/export.csv") into a cell.